Patents for A61P 35 - Antineoplastic agents (221,099)
02/2010
02/02/2010US7655408 PCA3 messenger RNA species in benign and malignant prostate tissues
02/02/2010US7655398 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
02/02/2010US7655251 Amphiphilicmonocatenary glycosylated hydrocarbon nitrones; oxidation resistance;free radical scavengers; neuroprotectants; cosmetic products for the skin, hair andnails; imunotherapy; antiinflammatory agents; Alzheimer's disease; Parkinson'sdisease; aging resistance; radiation injuries
02/02/2010US7655238 Fusing to the antigen a Listerial truncated ActA protein; Listeria vaccine strains
02/02/2010US7655030 Catheter balloon systems and methods
02/02/2010US7654957 Apparatus for physical measurements of the eye
02/02/2010CA2494583C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
02/02/2010CA2477756C Modified phosphocalcic compound, injectable composition containing same
02/02/2010CA2465090C Polymeric thiol-linked prodrugs employing benzyl elimination systems
02/02/2010CA2426043C Modulating angiogenesis
02/02/2010CA2410305C Preparations comprising combinations of enzyme inhibitors, and the use thereof
02/02/2010CA2396158C Dipeptide nitrile cathepsin k inhibitors
02/02/2010CA2383412C Cationic liposome delivery of taxanes to angiogenic blood vessels
02/02/2010CA2360228C Treatment of tumor metastases and cancer
02/02/2010CA2293724C Apaf-1, the ced-4 human homolog, an activator of caspase-3
02/02/2010CA2142331C Immunoglobulins devoid of light chains
01/2010
01/28/2010WO2010011994A2 Polypeptides and uses thereof
01/28/2010WO2010011856A2 Stereospecificity of methylsulfinyl reduction
01/28/2010WO2010011772A2 Tri-cyclic pyrazolopyridine kinase inhibitors
01/28/2010WO2010011768A1 Tri-cyclic pyrazolopyridine kinase inhibitors
01/28/2010WO2010011762A1 Pyrazolopyridine kinase inhibitors
01/28/2010WO2010011756A1 Pyrazolopyridine kinase inhibitors
01/28/2010WO2010011700A2 Treatment of cancers characterized by chromosomal rearrangement of the nut gene
01/28/2010WO2010011683A2 Methods for the cytological analysis of cervical cells
01/28/2010WO2010011666A2 Indoline scaffold shp-2 inhibitors and cancer treatment method
01/28/2010WO2010011622A2 Ophthalmic gallium compositions and methods of their use
01/28/2010WO2010011620A1 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
01/28/2010WO2010011599A2 Pimethixene derivatives for promoting bone growth
01/28/2010WO2010011538A1 Amidophenoxyindazoles useful as inhibitors of c-met
01/28/2010WO2010011349A2 Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use
01/28/2010WO2010011325A2 Synthesis and utilization of small molecules for the treatment of inflammation associated with interleukin-1 signaling
01/28/2010WO2010011319A2 Magnetic heating for drug delivery and other applications
01/28/2010WO2010011315A2 Proteins for use in diagnosing and treating infection and disease
01/28/2010WO2010011296A2 Deacetylase inhibitors and uses thereof
01/28/2010WO2010011289A2 Parenteral and oral formulations of benzimidazoles
01/28/2010WO2010011161A1 Method for producing live cell vaccine for preventing mammary cancer
01/28/2010WO2010010913A1 Method for producing bsh derivative and bsh derivative
01/28/2010WO2010010912A1 OPTICALLY ACTIVE α-AMINO ACID INTO WHICH BSH IS INTRODUCED AND METHOD FOR SYNTHESIZING THE SAME
01/28/2010WO2010010887A1 Tissue expression promoter
01/28/2010WO2010010797A1 Pharmaceutical composition comprising dyrk-inhibiting compound
01/28/2010WO2010010454A2 Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
01/28/2010WO2010010367A1 Solid pharmaceutical composition comprising exemestane
01/28/2010WO2010010347A1 Pyrrolobenzodiazepines
01/28/2010WO2010010288A2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof
01/28/2010WO2010010168A1 Transdermal pharmaceutical compositions comprising danazol
01/28/2010WO2010010154A1 3,4-diarylpyrazoles as protein kinase inhibitors
01/28/2010WO2010010112A2 Construct and method for the internalization of cargo molecules into a cell
01/28/2010WO2010009985A2 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
01/28/2010WO2010009967A1 Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
01/28/2010WO2010009905A1 Cancer treatment and test
01/28/2010WO2009152462A3 Method of regulating cell growth using a proteasome inhibitor
01/28/2010WO2009147530A3 Conformation specific antibodies that bind trefoil factors
01/28/2010WO2009136396A3 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases
01/28/2010WO2009126789A3 Engineering and delivery of therapeutic compositions of freshly isolated cells
01/28/2010WO2009122176A3 Rapamycin carbonate esters
01/28/2010WO2009120094A3 Substituted pyrimidines and triazines and their use in cancer therapy
01/28/2010WO2009111428A4 Methods for synthesizing glycinols, glyceollins i and ii, compositions of selected intermediates, and therapeutic uses thereof
01/28/2010WO2009107850A3 Fused heterocyclic derivative and use thereof
01/28/2010WO2009073445A3 Biocompatible biodegradable fumagillin analog conjugates
01/28/2010WO2009024631A3 A combination of inhibitors of tgfbeta-1 and matrix metalloproteins for use in the treatment of bone metastases, bone resorption and hypercalcaemia
01/28/2010WO2008137816A8 Tricyclic compounds as matrix metalloproteinase inhibitors
01/28/2010US20100022783 Cyclohexanecarboxylic acid compound
01/28/2010US20100022655 Therapeutic Agents For The Treatment Of Lymphoid Malignancies
01/28/2010US20100022637 Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
01/28/2010US20100022635 Heat shock protein 90 inhibitor dosing methods
01/28/2010US20100022632 Use certain diterpene compounds in the treatment of androgen receptor-associated diseases
01/28/2010US20100022630 Method of treatment using fatty acid synthesis inhibitors
01/28/2010US20100022626 Modulators of cell migration and methods of identifying same
01/28/2010US20100022622 Dbait and its Standalone Uses Thereof
01/28/2010US20100022621 Construction and use of transfection enhancer elements
01/28/2010US20100022609 Novel crystalline forms of temozolomide
01/28/2010US20100022607 Diazonamide analogs
01/28/2010US20100022600 Methods and compositions for treating central nervous system tumors
01/28/2010US20100022596 Epothilone analogues
01/28/2010US20100022593 Process for Producing Anticancer Agent LL-D45042
01/28/2010US20100022587 Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization
01/28/2010US20100022579 Substituted tetrahydroquinolines
01/28/2010US20100022569 Inhibitors of tyrosine kinases
01/28/2010US20100022564 Purine and deazapurine derivatives as pharmaceutical compounds
01/28/2010US20100022557 Radioprotector compounds and related methods
01/28/2010US20100022553 Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
01/28/2010US20100022540 Triazole derivatives ii
01/28/2010US20100022534 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
01/28/2010US20100022530 Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein
01/28/2010US20100022529 Amidophenoxyindazoles useful as inhibitors of c-met
01/28/2010US20100022522 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
01/28/2010US20100022514 Heterocycle Compounds and Methods of Use Thereof
01/28/2010US20100022512 Compositions of chk1 inhibitors and cyclodextrin
01/28/2010US20100022505 Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
01/28/2010US20100022495 Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
01/28/2010US20100022478 Chiral compounds substituted with phosphonate acid ester functions or phosphonic acid functions
01/28/2010US20100022477 Fused aromatic ptp-1b inhibitors
01/28/2010US20100022476 Pyrazolylamino substituted quinazoles for the treatment of cancer
01/28/2010US20100022473 Use of lipid conjugates in the treatment of diseases associated with vasculature
01/28/2010US20100022467 Anti-cancer phosphonate analogs
01/28/2010US20100022456 Dimeric Prolactin Receptor Ligands
01/28/2010US20100022448 Peptides
01/28/2010US20100022447 Composition for treating cancer and use thereof
01/28/2010US20100022016 Polyamide nucleic acid derivatives and agents, and processes for preparing them
01/28/2010US20100021995 Biological products